Private Sector Investing More Than Previously Thought In Efforts To Address Antimicrobial Resistance, Report Shows
Devex: Funding outlook shifts in fight against antimicrobial resistance
“Twenty-two research-based biopharmaceutical companies — including AstraZeneca, GlaxoSmithKline, and Merck — invested more than $2 billion in research and development to counter antimicrobial resistance in 2016, according to a survey released Thursday, potentially upending widespread perceptions that the private sector is trailing institutional donors in tackling AMR…” (Anders, 1/18).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.